A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 1

Conditions

Cancer

Treatments

Biological: V930

Biological: V932

Study type

Interventional

Funder types

Industry

Identifiers

V930-003

2007_671

Details and patient eligibility

About

Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens.

Full description

The optional followup period for this study is 1 year after the last vaccination.

Enrollment

41 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment
Patient must not be pregnant 3 days prior to enrollment

Exclusion criteria

Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent
Patient has had their spleen removed or has a history of autoimmune disorders
Patient is a regular user of any illicit drugs or has used within the past year of drug or alcohol abuse
Patient is pregnant or breastfeeding or is expecting to conceive anytime following the study
Patient is known to be Human Immunodeficiency Virus (HIV)-seropositive
Patient has a known history of Hepatitis B or C
Patient has received a vaccine for any disease or condition within one month of enrollment
Patient has a primary central nervous system tumor.